Valneva SE
PAR:VLA

Watchlist Manager
Valneva SE Logo
Valneva SE
PAR:VLA
Watchlist
Price: 3.786 EUR -2.17% Market Closed
Market Cap: 651m EUR

Valneva SE
Gross Profit

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Valneva SE
Gross Profit Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Gross Profit CAGR 3Y CAGR 5Y CAGR 10Y
Valneva SE
PAR:VLA
Gross Profit
€142.6m
CAGR 3-Years
27%
CAGR 5-Years
15%
CAGR 10-Years
20%
Nanobiotix SA
PAR:NANO
Gross Profit
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Inventiva SA
PAR:IVA
Gross Profit
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Cellectis SA
PAR:ALCLS
Gross Profit
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
DBV Technologies SA
PAR:DBV
Gross Profit
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Eurobio Scientific SA
PAR:ALERS
Gross Profit
€76.1m
CAGR 3-Years
-5%
CAGR 5-Years
15%
CAGR 10-Years
21%
No Stocks Found

Valneva SE
Glance View

Market Cap
614.8m EUR
Industry
Biotechnology

Valneva SE is a biotech company. The company is headquartered in Saint-Herblain, Pays De La Loire and currently employs 722 full-time employees. The company went IPO on 2007-06-28. The firm's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The firm has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The firm is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.

VLA Intrinsic Value
10.314 EUR
Undervaluation 63%
Intrinsic Value
Price

See Also

What is Valneva SE's Gross Profit?
Gross Profit
142.6m EUR

Based on the financial report for Jun 30, 2025, Valneva SE's Gross Profit amounts to 142.6m EUR.

What is Valneva SE's Gross Profit growth rate?
Gross Profit CAGR 10Y
20%

Over the last year, the Gross Profit growth was 66%. The average annual Gross Profit growth rates for Valneva SE have been 27% over the past three years , 15% over the past five years , and 20% over the past ten years .

Back to Top